Journal article icon

Journal article

Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer

Abstract:

Late-phase clinical trials investigating metformin as a cancer therapy are underway. However, there remains controversy as to the mode of action of metformin in tumors at clinical doses. We conducted a clinical study integrating measurement of markers of systemic metabolism, dynamic FDG-PET-CT, transcriptomics, and metabolomics at paired time points to profile the bioactivity of metformin in primary breast cancer. We show metformin reduces the levels of mitochondrial metabolites, activates mu...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1016/j.cmet.2018.08.021

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
ORCID:
0000-0001-7946-5609
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Expand authors...
Engineering and Physical Sciences Research Council More from this funder
NIHR Oxford Biomedical Research Centre More from this funder
Breast Cancer Research Foundation More from this funder
Publisher:
Cell Press Publisher's website
Journal:
Cell Metabolism Journal website
Volume:
28
Issue:
5
Pages:
679-688.e4
Publication date:
2018-09-20
Acceptance date:
2018-08-24
DOI:
ISSN:
1550-4131
Pubs id:
pubs:864243
URN:
uri:a9320331-ae91-42bb-bc6d-1fcd4384e020
UUID:
uuid:a9320331-ae91-42bb-bc6d-1fcd4384e020
Local pid:
pubs:864243

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP